Cargando…
Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma
Immune checkpoint inhibitors (ICPi) targeting the PD-1/PD-L1 pathway have shown marked success in patients with advanced melanoma. However, 60–70% of patients fail to respond, warranting a therapeutic intervention that could increase response rates. We and others have shown that S-adenosylmethionine...
Autores principales: | Mehdi, Ali, Attias, Mikhael, Mahmood, Niaz, Arakelian, Ani, Mihalcioiu, Catalin, Piccirillo, Ciriaco A., Szyf, Moshe, Rabbani, Shafaat Ahmed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492272/ https://www.ncbi.nlm.nih.gov/pubmed/32983966 http://dx.doi.org/10.3389/fonc.2020.01361 |
Ejemplares similares
-
Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone
por: Mehdi, Ali, et al.
Publicado: (2022) -
S‐adenosylmethionine in combination with decitabine shows enhanced anti‐cancer effects in repressing breast cancer growth and metastasis
por: Mahmood, Niaz, et al.
Publicado: (2020) -
Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications
por: Mahmood, Niaz, et al.
Publicado: (2017) -
An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis
por: Mahmood, Niaz, et al.
Publicado: (2020) -
S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas
por: Mehdi, A., et al.
Publicado: (2023)